Respiratory tract infections ‐ topical plus systemic prophylaxis versus systemic prophylaxis alone · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in respiratory tract infections ‐ topical plus systemic prophylaxis… compared with no topical prophylaxis (low certainty).
1 finding from 1 review
Respiratory infections · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis may leads to lower respiratory tract infections ‐ topical prophylaxis versus no… compared with no topical prophylaxis (low certainty).
2 findings from 1 review
Overall mortality ‐ topical plus systemic prophylaxis versus systemic prophylaxis alone · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in overall mortality ‐ topical plus systemic prophylaxis versus… compared with no topical prophylaxis (low certainty).
1 finding from 1 review
Overall mortality ‐ topical prophylaxis versus placebo or no treatment · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in overall mortality ‐ topical prophylaxis versus placebo or no treatment compared with no topical prophylaxis (moderate certainty).
1 finding from 1 review
Dropouts due to adverse events · adults receiving mechanical ventilation for at least 48 hours
It is very uncertain whether topical prophylaxis changes dropouts due to adverse events compared with no topical prophylaxis (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in gastrointestinal adverse events compared with no topical prophylaxis (low certainty).
1 finding from 1 review
Allergic adverse events · adults receiving mechanical ventilation for at least 48 hours
It is very uncertain whether topical prophylaxis changes allergic adverse events compared with no topical prophylaxis (very low certainty).
1 finding from 1 review
Overall mortality · adults receiving mechanical ventilation for at least 48 hours
Topical prophylaxis showed no clear difference in overall mortality compared with no topical prophylaxis (moderate certainty).
1 finding from 1 review
Overall mortality · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis leads to lower overall mortality compared with placebo or no treatment (high certainty).
1 finding from 1 review
Respiratory infections · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis probably leads to lower respiratory tract infections compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Dropouts due to adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in dropouts due to adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in gastrointestinal adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Allergic adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in allergic adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of pulmonary tuberculosis in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of pulmonary tuberculosis in children with HIV infection ‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention leads to lower episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pneumocystis carinii pneumonia infection in children with cancer ‐ trimethoprim‐sulfamethoxazole prophylaxis only · children with cancers aged 12 years and under
The intervention probably leads to lower incidence of Pneumocystis carinii pneumonia infection in children… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention probably leads to lower mortality in children with HIV infection ‐ co‐trimoxazole… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ isoniazid prophylaxis only (low certainty).
1 finding from 1 review